Serum DR-70 as Biomarker in Breast Cancer

Buldanlı, Mehmet Zeki; Özemir, İbrahim Ali; Çolapkulu, Nuray; Baysal, Hakan; Ekinci, Özgür; Yener, Oktay; Kahraman, Nevin Genc; Ali̇moğlu, Orhan

doi:10.1007/s12262-022-03321-7

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Affected patients generate fibrinogen and fibrin degradation products to restrict cancer cells, and the DR-70 assay measures both fibrinogen and fibrin degradation. 10,15,16 The commercial D-dimer immunoassay specifically determines the epitope on the degradation products of factor XIII-cross-linked fibrin, but fails to detect fibrinogen degradation products. 13,14 As an ideal tumor biomarker, tests that only measure D-dimer will miss up to half of the actual FDPs produced by tumors.…”

Section: Fibrinogen Degradation Products and Fibrin Degradation Productsmentioning

confidence: 99%

“…Therefore, D‐dimer is a specific fibrin degradation product that results from fibrinolysis. Affected patients generate fibrinogen and fibrin degradation products to restrict cancer cells, and the DR‐70 assay measures both fibrinogen and fibrin degradation 10,15,16 . The commercial D‐dimer immunoassay specifically determines the epitope on the degradation products of factor XIII‐cross‐linked fibrin, but fails to detect fibrinogen degradation products 13,14 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increased plasma DR‐70 (fibrinogen‐fibrin degradation products) concentrations as a diagnostic biomarker in dogs with neoplasms

Ke,

Sio,

et al. 2023

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundTumor biomarkers have used widely in clinical oncology in human medicine. Only a few studies have evaluated the clinical utility of tumor biomarkers for veterinary medicine. A test for fibrinogen and fibrin degradation products (DR‐70) has been proposed as an ideal biomarker for tumors in humans. The clinical value of DR‐70 for veterinary medicine however has yet to be determined.ObjectivesInvestigate the diagnostic value of DR‐70 concentrations by comparing them between healthy dogs and dogs with tumors.AnimalsTwo hundred sixty‐three dogs with different types of tumors were included. Sixty healthy dogs also were recruited for comparison.MethodsThe DR‐70 concentrations were measured in all recruited individuals by ELISA. Clinical conditions were categorized based on histopathology, cytology, ultrasound examination, radiology, clinical findings, and a combination of these tests.ResultsThe median concentration of DR‐70 was 2.130 ± 0.868 μg/mL in dogs with tumors, which was significantly higher than in healthy dogs (1.202 ± 0.610 μg/mL; P < .0001). With a cut‐off of 1.514 μg/mL, the sensitivity and specificity of DR‐70 were 84.03% and 78.33%, respectively. The area under curve was 0.883. The DR‐70 concentration can be an effective tumor biomarker in veterinary medicine.Conclusions and Clinical ImportanceIncreased DR‐70 concentrations were not affected by tumor type, sex, age, or body weight. However, in dogs with metastatic mast cell tumors and oral malignant melanoma, DR‐70 concentrations were significantly increased. Additional studies, including more dogs with nonneoplastic diseases, are needed to further evaluate the usefulness of DR‐70 as a tumor biomarker.

show abstract